120 related articles for article (PubMed ID: 3409242)
1. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
Hadidi AH; Coulter CE; Idle JR
Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242
[TBL] [Abstract][Full Text] [Related]
2. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide metabolism in children.
Yule SM; Boddy AV; Cole M; Price L; Wyllie R; Tasso MJ; Pearson AD; Idle JR
Cancer Res; 1995 Feb; 55(4):803-9. PubMed ID: 7850793
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
5. Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites.
Hadidi AH; Idle JR
J Chromatogr; 1988 May; 427(1):121-30. PubMed ID: 3410892
[TBL] [Abstract][Full Text] [Related]
6. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
8. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
10. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
11. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
12. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
Fetting JH; McCarthy LE; Borison HL; Colvin M
Cancer Treat Rep; 1982 Aug; 66(8):1625-9. PubMed ID: 7105052
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
15. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro.
Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP
J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954
[TBL] [Abstract][Full Text] [Related]
16. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
17. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
[TBL] [Abstract][Full Text] [Related]
20. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
Hales BF
Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
